BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox
We already knew from BioMarin’s statement a few days ago that their gene therapy for hemophilia A continued to protect patients against the bleeding …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
